Stephen D. Weigand

Active 2004–2025

142
Papers
33,273
Citations
93
h-index
138
i10-index

Citations

Citations per year for Stephen D. Weigand1940: 1 citations1990: 1 citations1993: 1 citations2000: 1 citations2001: 1 citations2003: 2 citations2004: 12 citations2005: 44 citations2006: 63 citations2007: 107 citations2008: 187 citations2009: 242 citations2010: 309 citations2011: 418 citations2012: 426 citations2013: 558 citations2014: 525 citations2015: 564 citations2016: 510 citations2017: 573 citations2018: 590 citations2019: 1,549 citations2020: 1,523 citations2021: 1,527 citations2022: 1,220 citations2023: 890 citations2024: 1,375 citations2025: 646 citations2026: 40 citations1941–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown1994–1999: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,003 citing papers, 28.6% of this breakdownUnited Kingdom: 1,640 citing papers, 9.4% of this breakdownGermany: 1,024 citing papers, 5.9% of this breakdownChina: 865 citing papers, 4.9% of this breakdownCanada: 851 citing papers, 4.9% of this breakdownSweden: 805 citing papers, 4.6% of this breakdownItaly: 785 citing papers, 4.5% of this breakdownNetherlands: 750 citing papers, 4.3% of this breakdownFrance: 651 citing papers, 3.7% of this breakdownAustralia: 584 citing papers, 3.3% of this breakdownSpain: 571 citing papers, 3.3% of this breakdownSwitzerland: 422 citing papers, 2.4% of this breakdown
0%28.6%Other 20.2%

Fields

  • Medicine75%
  • Neuroscience14.8%
  • Biochemistry, Genetics and Molecular Biology4.6%
  • Computer Science1.6%
  • Psychology1.1%
  • Immunology and Microbiology0.5%
  • Other2.4%

Topics

  • Dementia and Cognitive Impairment Research15.2%
  • Alzheimer's disease research and treatments15%
  • Functional Brain Connectivity Studies5.6%
  • Advanced Neuroimaging Techniques and Applications3.3%
  • Multiple Sclerosis Research Studies3.2%
  • Neuroinflammation and Neurodegeneration Mechanisms2.8%
  • Other54.9%

Coauthors

All papers

Open in search
  1. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

    Authors: , , , , , , , , , , , , , - The Lancet Neurology 2013 cited by 4,416

  2. Defining imaging biomarker cut points for brain aging and Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2016 cited by 970

  3. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque

    Authors: , , , , , , , , , , , - Annals of Neurology 2015 cited by 710

  4. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , - Acta Neuropathologica 2014 cited by 487

  5. Longitudinal tau PET in ageing and Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , - Brain 2018 cited by 461

  6. Inflammatory Cortical Demyelination in Early Multiple Sclerosis

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 1,086

  7. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity

    Authors: , , , , , , , , , , , , , , - NeuroImage Clinical 2016 cited by 445

  8. Updated TDP-43 in Alzheimer’s disease staging scheme

    Authors: , , , , , , , , , - Acta Neuropathologica 2016 cited by 379

  9. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework

    Authors: , , , , , , , , , , , , , , , , - JAMA Neurology 2019 cited by 307

  10. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia

    Authors: , , , , , , , , , , , , , , , , - JAMA 2019 cited by 336

  11. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study

    Authors: , , , , , , , , , , , , , - The Lancet Neurology 2017 cited by 253

  12. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

    Authors: , , , , , , , , , , , - Brain 2009 cited by 1,093

  13. Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays

    Authors: , , , , , , , , , , - Alzheimer s & Dementia 2021 cited by 86

  14. Brain β-amyloid load approaches a plateau

    Authors: , , , , , , , , , , , , - Neurology 2013 cited by 409

  15. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

    Authors: , , , , , , , , , , , , , , , , , , , - Brain 2019 cited by 208

  16. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study

    Authors: , , , , , , , , , , , - The Lancet Neurology 2012 cited by 440

  17. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

    Authors: , , , , , , , , , , , , , - The Lancet Neurology 2017 cited by 353

  18. Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia

    Authors: , , , , , , , , , , , , , , , , , , , , - Brain 2017 cited by 309

  19. Age, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span

    Authors: , , , , , , , , , , , , , - JAMA Neurology 2015 cited by 393

  20. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

    Authors: , , , , , , , , , , - Brain 2008 cited by 967

  21. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

    Authors: , , , , , , , , , , , , - Brain 2015 cited by 256

  22. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

    Authors: , , , , , , , , , , , , , - Annals of Neurology 2011 cited by 603

  23. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , - Brain 2010 cited by 541

  24. MRI correlates of neurofibrillary tangle pathology at autopsy

    Authors: , , , , , , , , , , , , , - Neurology 2008 cited by 368